NIPT Special
from the 11th week of pregnancy
Goals
- Completely risk-free screening for chromosomal abnormalities (trisomy 13, 18, and 21) at the earliest possible stage of pregnancy
Cost of the examination
€800
The NIPT (Non-Invasive Prenatal Test) determines whether there is a risk of genetic chromosome abnormalities by analyzing snippets of fetal DNA found in the mother's blood. NIPT can detect 99.9% of Trisomy 21 cases. Furthermore, the test provide information on the risks for Trisomy 18 and 13, and the chromosomal sex can also be determined.
Starting from the 11th week of pregnancy, the blood draw for the NIPT (Non-Invasive Prenatal Test) can be performed at any time throughout the remaining course of the pregnancy. It is recommended to always combine the NIPT with an ultrasound examination.
The NIPT Special: Innovative genetic analysis for maximum safety with hidden risks
The Non-Invasive Prenatal Test (NIPT) requires only a simple blood draw, making it a completely risk-free alternative for both mother and child compared to chorionic villus sampling and amniocentesis.
The NIPT involves testing the maternal blood, which contains the baby's DNA. An analysis of these fragments of fetal genetic material is used to determine the risk of a genetic abnormality in the unborn child.
The NIPT Special is currently the only prenatal test worldwide that screens for cystic fibrosis, spinal muscular atrophy, sickle cell disease, and thalassemias. Single-gene disorders are only very rarely detectable using ultrasound. In contrast, this test detects the mutations that can lead to cystic fibrosis, spinal muscular atrophy, sickle cell disease, or thalassemias (α- and β-thalassemias) with a detection rate of 98.5 percent. The false-positive rate is 1 percent.
The NIPT is recommended in combination with the first-trimester ultrasound scan, including preeclampsia screening. This early screening examination can detect or rule out up to 65 percent of malformations that do not have an immediate genetic cause. These cannot be detected with the NIPT.
The Non-Invasive Prenatal Test is also offered as a two-part examination. It can be performed as early as the 11th week of pregnancy, which usually provides parents with early reassurance. If the NIPT is carried out early (11th week of pregnancy), we recommend performing the first-trimester ultrasound, including pre-eclampsia screening, between the 12th and 14th week of pregnancy.
For twin pregnancies and pregnancies with donor eggs, an NIPT Extended is not possible.
- The results will be available approx. 14 working days after the examination.
Investigation Timeline
Our prenatal center is equipped with its own laboratory. This makes it possible to carry out examinations entirely in our facility and to inform you of the results very quickly.
Book an appointment
Our prenatal center is equipped with its own laboratory. This allows us to perform all examinations entirely in-house.
Cost of the examination
€800Q&A
The NIPT is currently the best risk-free test for determining the probability of chromosomal disorders. In principle, any pregnant woman can opt for this test. The NIPT is recommended for those with an intermediate risk between 1:300 and 1:1,000 after the Combined Test, or as a primary test in cases of higher background risk.
During NIPT (Non-invasive Prenatal Testing), fetal DNA fragments that can be detected in the maternal blood are analyzed using molecular biological methods. These are detectable from gestational week 10 +0.
There are various non-invasive prenatal tests (NIPTs) that vary in their scope. The recommended NIPT used at the Prenatal Center at the Wien screens for trisomy 21, trisomy 18 and 13, as well as the baby's chromosomal sex. In addition, the child's Rhesus factor, triploidies, cystic fibrosis, and other diseases can be tested with varying detection rates.
The costs for the NIPT (non-invasive prenatal test) depend on the scope of the test. We offer 5 different test packages – please refer to our price list for the corresponding prices.
The NIPT (non-invasive prenatal test) is the most reliable non-invasive test for determining the risk of Down syndrome. The detection rate is over 99% for trisomy 21.